Utah is currently home to 1209 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Salt Lake City, Murray, Ogden and West Jordan. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
NCT04868877
Recruiting
A phase 1/2 open-label multicenter study will be performed with an initial dose escalation part to determine the MTD and/or the RP2D of MCLA-129 in monotherapy or in combination in patients with NSCLC, HNSCC, GC/GEJ, ESCC, or other solid tumors and who are treatment naïve or have progressed after receiving prior therapy for advanced/metastatic disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: START Mountain Region, West Valley City, Utah
Conditions: Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
Register for Updates
Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer.
NCT04549116
Recruiting
This is a multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority clinical study in women aged 35 to 42 years. This study will investigate the safety and efficacy of Progesterone-IBSA to support euploid embryo blastocyst implantation and early pregnancy after frozen embryo transfer (FET) in a modified natural cycle as a treatment for infertile women. Subjects will be randomized to receive either active Progesterone-IBSA or Crinone 8% for luteal and early pregnancy... Read More
Gender:
FEMALE
Ages:
Between 35 years and 42 years
Trial Updated:
06/23/2025
Locations: Utah Fertility Center, PC, Pleasant Grove, Utah
Conditions: Infertility
Register for Updates
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
NCT04262206
Recruiting
PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.
Gender:
ALL
Ages:
75 years and above
Trial Updated:
06/23/2025
Locations: Intermountain, Murray, Utah
Conditions: Cognitive Impairment, Mild, Dementia, Cardiovascular Diseases
Register for Updates
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046
Recruiting
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: University of Utah Healthcare, Salt Lake City, Utah
Conditions: Intracerebral Hemorrhage, Atrial Fibrillation
Register for Updates
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
NCT06500273
Recruiting
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2025
Locations: Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
Conditions: Large B-cell Lymphoma
Register for Updates
Precision Ventilation vs Standard Care for Acute Respiratory Distress Syndrome
NCT06066502
Recruiting
The goal of this interventional study is to compare standard mechanical ventilation to a lung-stress oriented ventilation strategy in patients with Acute Respiratory Distress Syndrome (ARDS). Participants will be ventilated according to one of two different strategies. The main question the study hopes to answer is whether the personalized ventilation strategy helps improve survival.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2025
Locations: Intermountain Health, Murray, Utah
Conditions: Acute Respiratory Distress Syndrome, Respiratory Failure
Register for Updates
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
NCT05669482
Recruiting
This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreated.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2025
Locations: University of Utah Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer, Neoplasms Pancreatic, Malignant Neoplasm of Pancreas
Register for Updates
5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer
NCT06961955
Recruiting
The goal of this study is to evaluate 5 days vs. 9 days of whole breast radiation.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Conditions: Breast Cancer, Invasive Carcinoma of Breast, Ductal Breast Carcinoma in Situ
Register for Updates
Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphomas
NCT06824701
Recruiting
The purpose of this clinical trial is to learn if the study drug Tazemetostat combined with Zanubrutinib and anti-CD20 monoclonal antibody is safe and effective in treating patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: Huntsman Cancer Institute at University of Uta, Salt Lake City, Utah
Conditions: Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Register for Updates
A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants
NCT06813924
Recruiting
The study aims to test if a new medicine called etavopivat potentially affects other medicines in healthy participants. The purpose of the study is to investigate whether the use of etavopivat affects the breakdown and metabolism of commonly used medicines in the body. During the study, participants will receive etavopivat and five different medicines that are already approved and available on the market, and which can be prescribed by doctors. These marketed medicines are called substrate drugs... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/19/2025
Locations: ICON-Salt Lake City, Salt Lake City, Utah
Conditions: Healthy Volunteers Sickle Cell Disease, Thalassemia
Register for Updates
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors
NCT06431594
Recruiting
The goal of this study is to assess the safety and tolerability of GSK5733584. The study will also see how the levels of GSK5733584 change over time at different dose amount.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: GSK Investigational Site, West Valley City, Utah
Conditions: Solid Tumors, Neoplasms
Register for Updates
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
NCT05879367
Recruiting
The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, GBM, Astrocytoma, Astrocytoma, IDH-Mutant
Register for Updates